NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.33 -0.04 (-0.63 %)
(As of 04/24/2019 03:54 PM ET)
Previous Close$6.37
Today's Range$6.16 - $6.44
52-Week Range$6.15 - $32.90
Volume157,339 shs
Average Volume553,912 shs
Market Capitalization$173.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.05 million
Book Value$3.29 per share

Profitability

Net Income$-131,000,000.00
Net Margins-384.77%

Miscellaneous

Employees159
Market Cap$173.75 million
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) posted its quarterly earnings data on Monday, March, 4th. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.30. The specialty pharmaceutical company had revenue of $13.32 million for the quarter, compared to analyst estimates of $13.30 million. Adamas Pharmaceuticals had a negative net margin of 384.77% and a negative return on equity of 101.46%. View Adamas Pharmaceuticals' Earnings History.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Adamas Pharmaceuticals.

What price target have analysts set for ADMS?

8 brokerages have issued 12 month price objectives for Adamas Pharmaceuticals' stock. Their predictions range from $5.00 to $40.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $22.2857 in the next twelve months. This suggests a possible upside of 252.1% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

What is the consensus analysts' recommendation for Adamas Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

What are Wall Street analysts saying about Adamas Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (3/5/2019)
  • 2. Northland Securities analysts commented, "We remain confident in GOCOVRI’s success, along w/ significant upside potential from ADS-5102 for MS walking impairment. GOCOVRI sales for ’18 totaled $34MM, comparing to $22.5MM at the time of our initiation of coverage in late-2017. While sequential Rx growth has slowed, we anticipate sustained sequential growth supporting our OP rating. Adamas reported 4Q results w/ GOCOVRI sales at $13.3MM, aligned with guidance provided in early-January. Paid prescriptions for the 4Q period totaled 5,730, up sequentially from 4,740. R&D and SG&A expense line items totaled $10.6MM and $27.6MM, respectively, which were lower than expected. EPS tracked ($1.06) vs. the consensus of ($1.33), attributable to lower-than-anticipated operating expenses. The Co. ended the December 31st 2018 period w/ cash of $211MM, w/ cash used in the 4Q period ~$22MM." (3/5/2019)
  • 3. Mizuho analysts commented, "We see minimal 2019 catalysts or take-out possibility for Adamas, and reiterate our Neutral rating. We also believe the stock will be pressured by the recent launch of Osmolex ER. We updated our model following guidance on 2019 Gocovri growth and a 7.75% price increase, with no change to our $11 PT." (1/11/2019)

Has Adamas Pharmaceuticals been receiving favorable news coverage?

Media coverage about ADMS stock has been trending somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.

Who are some of Adamas Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Exelixis (EXEL), Omeros (OMER), ACADIA Pharmaceuticals (ACAD), Flexion Therapeutics (FLXN), Micron Technology (MU), Synergy Pharmaceuticals (SGYP) and AbbVie (ABBV).

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
  • Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
  • Ashleigh Barreto, Director of Corp. Communications & Investor Relations
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (1.96%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Which major investors are buying Adamas Pharmaceuticals stock?

ADMS stock was acquired by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $6.33.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $173.75 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]


MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel